Amneal Co-CEO reports 6.38M share acquisition
Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026. This equity was received as part of Amneal’s acquisition of Kashiv BioSciences, LLC, alongside cash consideration and other share issuances. Following this transaction, Patel also holds 1,388,521 shares directly and 24,753,252 shares indirectly through family trusts.
Insider Trade Summary
Grant/Award: 6,381,734 shares
Grant/Award
3 txns
Insider
Patel Chintu
Role
Co-CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock F1 | 6,381,734 | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 6,381,734 shares (Indirect, By Limited Liability Companies);
Class A Common Stock — 1,388,521 shares (Direct);
Class A Common Stock — 24,753,252 shares (Indirect, By Family Trusts)
Footnotes (1)
- F1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.
Key Figures
Shares received by managed LLCs: 6,381,734 shares of Class A Common Stock
Cash consideration for Kashiv: $375,000,000
Total shares issued as Kashiv consideration: 28,942,098 shares of Class A Common Stock
+2 more
5 metrics
Shares received by managed LLCs
6,381,734 shares of Class A Common Stock
Equity consideration to limited liability companies managed by Chintu Patel in the Kashiv acquisition on August 10, 2026
Cash consideration for Kashiv
$375,000,000
Aggregate cash consideration for 100% of Kashiv BioSciences membership interests, subject to purchase price adjustments
Total shares issued as Kashiv consideration
28,942,098 shares of Class A Common Stock
Share component of consideration for Kashiv BioSciences acquisition
Direct holdings after transaction
1,388,521 shares of Class A Common Stock
Shares directly held by Chintu Patel following the reported transactions
Indirect family trust holdings
24,753,252 shares of Class A Common Stock
Shares held indirectly by Chintu Patel through family trusts after the reported transactions
Key Terms
Membership Interest Purchase Agreement, purchase price adjustments, Class A Common Stock, Family Trusts
4 terms
Membership Interest Purchase Agreement financial
"pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026"
A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.
purchase price adjustments financial
"for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments"
Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.
Class A Common Stock financial
"and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock)"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Family Trusts financial
"total_shares_following_transaction 24,753,252.0000, nature_of_ownership By Family Trusts"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AMRX Co-CEO Chintu Patel report in this Form 4 transaction?
Co-CEO Chintu Patel reported an indirect acquisition of 6,381,734 shares of Amneal Class A Common Stock on August 10, 2026, received by limited liability companies he manages as part of the Kashiv BioSciences acquisition.
What were the total consideration terms in Amneal’s acquisition of Kashiv BioSciences (AMRX)?
Amneal’s subsidiary acquired Kashiv for $375,000,000 in cash, subject to purchase price adjustments, plus 28,942,098 shares of Amneal Class A Common Stock. A portion of these shares, 6,381,734, went to limited liability companies managed by Chintu Patel.
Is the AMRX Form 4 transaction a market purchase or part of an acquisition?
The Form 4 entry reflects an acquisition-related equity issuance, not a market trade. The 6,381,734 shares were issued to limited liability companies managed by Chintu Patel as consideration in Amneal’s purchase of Kashiv BioSciences, LLC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates